Summary
Cancer Genetics, Inc. (CGI) is a pharmaceutical company which offers diagnostics products and services in the area of oncology. Its products include DNA-FISH Probes, CGH Microarrays and Next-Generation Sequencing. CGI’s oncology tests and laboratory services provide critical genomic information to healthcare professionals, biopharma companies, and cancer centers. The company provides clinical services such as test menu, complete program, expand DX and summation report. It collaborates with Cleveland Clinic, Dana Farber Cancer Institute, Georgia Health Sciences University, Hackensack University Medical Center, Kamineni Hospital, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, and National Cancer Institute. CGI is headquartered in Rutherford, New Jersey, the US.
Cancer Genetics, Inc. (CGIX) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cancer Genetics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Cancer Genetics, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 7
Cancer Genetics, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Cancer Genetics, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 9
Cancer Genetics, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 10
Cancer Genetics, Inc., Medical Equipment, Deal Details 11
Asset Purchase 11
Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11
Venture Financing 13
Cancer Genetics Raises US$6.6 Million In Venture Financing 13
Partnerships 14
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 14
Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 15
Equity Offering 16
Cancer Genetics Raises USD12 Million in Public Offering of Shares 16
Cancer Genetics Completes Public Offering Of Shares For US$46 Million 18
Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 20
Cancer Genetics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 22
Cancer Genetics Completes IPO For US$7 Million 24
Cancer Genetics, Inc. - Key Competitors 26
Key Employees 27
Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Strategy And Business Planning 29
Feb 05, 2016: Cancer Genetics Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota 29
Sep 08, 2015: Cancer Genetics Increases Access to Proprietary Diagnostics Tests as Part of New Agreement With Blue Cross Blue Shield of Illinois 30
Jul 06, 2015: Cancer Genetics Announces a Partnership with ICON to Offer Comprehensive Oncology Laboratory Testing & Solutions for the Global Biopharma Industry 31
May 22, 2015: Cancer Genetics Appoints Mandar Kulkarni, Ph.D., as Chief Technology Officer of Cancer Genetics, India 32
Apr 01, 2015: Cancer Genetics Increases Access to its Comprehensive Cancer Diagnostic Tests & Services through Agreement with America’s Choice Provider Network 33
Financial Announcements 34
Mar 10, 2016: Cancer Genetics Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update 34
Nov 10, 2015: Cancer Genetics Announces Strong Third Quarter and Year-to Date 2015 Results 35
Aug 11, 2015: Cancer Genetics Announces Strong Second Quarter 2015 Results 37
May 12, 2015: Cancer Genetics Announces Strong First Quarter 2015 Results 39
Mar 12, 2015: Cancer Genetics Announces Record Fourth Quarter and Full-Year 2014 Revenue 41
Corporate Communications 43
Jul 09, 2015: Cancer Genetics Appoints Rita Shaknovich, M.D., Ph.D., as Group Medical Director and Vice President of Hematopathology Services 43
Feb 11, 2015: Cancer Genetics Appoints Randy Goodman, Ph.D., as Director of Reimbursement and Clinical Revenue Cycle Management 44
Legal and Regulatory 45
Oct 02, 2015: Cancer Genetics Receives Bankruptcy Court Approval to Purchase Los Angeles-Based Response Genetics 45
Jan 05, 2015: Cancer Genetics Receives Approval to Provide Oncology Testing for Patients in California 46
Product News 47
Oct 28, 2015: Cancer Genetics Receives Third Patent for Proprietary Genomic FHACT test, Further Advancing the Detection and Treatment of Cervical and Other HPV-Associated Cancers 47
Apr 21, 2015: Cancer Genetics Expands Next-Generation Sequencing Capabilities In India Through Launch of Solid Tumor Hotspot Panel For Biopharma and Clinical Customers Throughout Asia 48
Apr 16, 2015: Cancer Genetics Receives New York State Licensure for FHACT Cervical Cancer Test 49
Mar 23, 2015: Cancer Genetics to Present Results from Three Major Clinical Research Collaborations at USCAP Showcasing the Importance of Genomic Panels for Cancer Identification and Management 50
Feb 17, 2015: Cancer Genetics' Unique, Next Generation Sequencing Panel for Chronic Lymphocytic Leukemia Selected for Use in Global Clinical Trial by Leading Biotechnology Company 51
Other Significant Developments 52
Nov 09, 2015: Cancer Genetics Expands the Availability of Genomic Testing as It Signs In-Network Provider Agreements With Blue Cross Blue Shield of North Carolina Blue Cross Blue Shield Nebraska and Wellmark 52
Jul 16, 2015: Cancer Genetics Announces the Expansion of Access to its Proprietary Diagnostic Tests Through Agreement with Harvard Pilgrim Healthcare 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Tables
Cancer Genetics, Inc., Medical Equipment, Key Facts, 2014 1
Cancer Genetics, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 1
Cancer Genetics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Cancer Genetics, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 7
Cancer Genetics, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Cancer Genetics, Inc., Deals By Market, 2010 to YTD 2016 9
Cancer Genetics, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 10
Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11
Cancer Genetics Raises US$6.6 Million In Venture Financing 13
Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 14
Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 15
Cancer Genetics Raises USD12 Million in Public Offering of Shares 16
Cancer Genetics Completes Public Offering Of Shares For US$46 Million 18
Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 20
Cancer Genetics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 22
Cancer Genetics Completes IPO For US$7 Million 24
Cancer Genetics, Inc., Key Competitors 26
Cancer Genetics, Inc., Key Employees 27
Cancer Genetics, Inc., Subsidiaries 28
List of Figures
Cancer Genetics, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016 1
Cancer Genetics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 1
Cancer Genetics, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 1
Cancer Genetics, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 1
Cancer Genetics, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Cancer Genetics, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016 7
Cancer Genetics, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Cancer Genetics, Inc., Medical Equipment, Deals by Market, 2010 to YTD 2016 9
